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Reagent substitutions in the Centers for Disease Control and 
Prevention Nijmegen-Bethesda assay for factor VIII inhibitors
C. H. Miller, A. B. Payne, J. Driggers, D. Ellingsen, B. Boylan, and C. J. Bean
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, 
Centers for Disease Control and Prevention, Atlanta, GA, USA
The Nijmegen-Bethesda assay (NBA), considered the “gold standard” for measurement of 
factor VIII (FVIII) inhibitors in haemophilia A,1 introduced two modifications to the 
traditional Bethesda assay (BA) for stabilization during the 2-hour incubation at 37°C: (i) 
buffering of normal pooled plasma (NPP) in the test and control mixtures with imidazole 
and (ii) substitution of FVIII-deficient plasma (FVIIIDP) for imidazole buffer (IB) in the 
control mixture and for specimen predilution.2 The NBA has not been widely adopted in the 
United States, because of the increased cost incurred by use of FVIIIDP rather than buffer 
and the lack of FDA-approved commercial reagents.3 Surveys of North American 
coagulation laboratories have shown that only 20% use the NBA, 70% use buffered NPP in a 
“hybrid” of the NBA and BA, and one-third use diluents other than those recommended in 
published methods.3 This lack of methodological uniformity may partially account for poor 
interlaboratory reproducibility, a well-known problem with FVIII inhibitor testing.3
Verbruggen et al4 proposed that a 4% bovine serum albumin solution (BSA) could be 
substituted for FVIIIDP in the NBA based on the study of 6 inhibitor-positive specimens; 
however, Kershaw and colleagues5 found FVIIIDP and BSA results to be significantly 
different among 72 specimens. In a study of four specimens of various titres in 6 
laboratories, imidazole buffer alone as diluent was reported to show equivalent results to 
FVIIIDP.6 We performed this study to clarify whether reagents could be successfully 
substituted in the Centers for Disease Control (CDC)-modified Nijmegen-Bethesda assay 
(CDC- NBA)7 and to document the performance characteristics of the assay with these 
changes.
FVIII coagulant activity (VIII:C) in International Units per decilitre (IU/dL) was measured 
by one-stage assay using PTT-A reagent (Diagnostica Stago, Parsippany, NJ, USA), 0.05 M 
imidazole buffer pH 7.4 (Siemens, Marburg, Germany) as analyser diluent, FVIIIDP from 
haemophilic subjects (George King Biomedical, Overland Park, KS, USA) as substrate and 
normal reference plasma (CCNRP; Precision Biologic, Dartmouth, Nova Scotia, Canada) 
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diluted in 0.05 M imidazole buffer pH 7.4 (Siemens) as calibrator. Specimens from 
haemophilia A patients enrolled in the Registry for Bleeding Disorder Surveillance were 
processed and shipped to CDC as previously described.7 FVIII inhibitors in Nijmegen-
Bethesda units (NBU) were measured by NBA,2 modified as previously described 7 with 
heating of specimens to 56°C for 30 minutes and then centrifuging at 2700 g for 5 minutes 
at room temperature prior to testing. Imidazole-buffered NPP (Precision Biologic) (IB-NPP) 
was used in control and test mixtures, and naturally deficient FVIIIDP (George King 
Biomedical) was used in control mixtures and for predilution of those specimens requiring 
dilution (<25% residual activity, >2.0 NBU). For comparison, assays were run concurrently 
with other diluents substituted for FVIIIDP both in the control mixture with IB-NPP and for 
predilution of positive specimens requiring dilution. Diluents tested were 4% bovine serum 
albumin (BSA) (Equitech, Kerrville, TX, USA; A-3059, Sigma-Aldrich Corp., St. Louis, 
MO, USA), 4% bovine serum albumin (Sigma) in 100 mM imidazole buffer (IB-BSA) and 
0.05 M imidazole buffer (Siemens) (IB). Positive controls were inhibitor-positive patient 
plasmas (George King Biomedical) diluted in FVIIIDP to approximately 1.0 NBU. 
Statistical analyses were conducted using GRAPHPAD Prism version 6.0 and SAS version 
9.3. A significance level of P < .05 was used.
The effect of the NPP preparation used in the control mixture on its stability was evaluated 
using NPP (Precision Biologic) unbuffered and buffered with imidazole (Sigma-Aldrich) or 
with 4-(2-hydroxyethy l)-1-piperazineethanesulfonic acid (HEPES) (Acros Organics, 
Fairfield, NJ, USA) to pH 7.4 and mixed 1:1 with FVIIIDP, BSA or an inhibitor- negative 
patient plasma in duplicate. VIII:C and pH were measured in duplicate before and after 2 
hours of incubation at 37°C (Figure 1A). Both VIII:C and pH showed the least change in the 
imidazole-buffered NPP and BSA mixture.
The effect of the diluent used in the control mixture on its stability was examined using a 1:1 
mixture of IB-NPP with BSA, IB-BSA or IB prepared in triplicate and tested for VIII:C in 
duplicate after 0, 30, 60 and 120 minutes of incubation at 37°C (Figure 1B). The FVIIIDP 
mixture decreased to 85% of its original value of 49 IU/dL. BSA and IB-BSA mixtures 
showed a slight increase to 107% of the original means of 42 and 43 IU/dL. The IB mixture 
maintained 97% of its original 45 IU/dL. Using ANOVA, the BSA, IB-BSA and IB curves 
were not significantly different from each other; each showed significantly less change 
during incubation than the FVIIIDP mixture. This is in contrast to the original observation of 
maintenance of 95% of pre-incubation activity using FVIIIDP in the NBA.2
Specimens not requiring predilution (<2.0 NBU) were tested with BSA, IB-BSA and IB 
substituted for FVIIIDP in the control mixture (Table 1A). Results for 15 positive specimens 
(0.5–1.9 NBU with FVIIIDP) were not significantly different; 311 negative specimens (<0.5 
NBU with FVIIIDP) gave slightly but significantly higher NBU when the nonplasma 
diluents were used. Using FVIIIDP as the “gold standard,” the ability to correctly assign 
inhibitor status was compared for each diluent by evaluating the area under the receiver 
operating characteristic (ROC) curve. The diluents were not significantly different (P = 0.9).
For further comparisons, BSA was substituted in paired testing of 1239 specimens of 0–
747.3 NBU. Median FVIIIDP and BSA results on 33 positive (≥0.5 NBU) specimens were 
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not significantly different by Wilcoxon matched-pairs signed-rank test (P = .57). Results 
differed significantly (P < .0001) on specimens with negative inhibitor titres (<0.5 NBU) 
with median for FVIIIDP of 0.0 NBU and for BSA of 0.2 NBU and a median of differences 
of 0.20 NBU. The 1.0 NBU positive control was also higher with BSA than with FVIIIDP, 
with medians of 1.2 and 1.0 NBU, respectively (P < .0001), and a median of differences of 
0.20 NBU. Using BSA and a threshold for positivity of ≥0.5 NBU, 62 (5.1%) of the 1206 
specimens that were negative with FVIIIDP were misclassified as positive, 48 of them at 0.5 
NBU. When ≥0.6 NBU was used as the threshold for positivity for BSA, 14 specimens 
(1.2%) negative with FVIIIDP were classified as positive with BSA. A single specimen 
positive with FVIIIDP was negative with BSA using both cut-offs. This specimen was 
negative by chromogenic Bethesda assay and may represent a false positive with FVIIIDP. 
Comparison of the performance characteristics of the CDC-NBA using FVIIIDP and BSA is 
shown in Table 1B.
The limit of detection (LOD) for the standard CDC-NBA was previously calculated to be 0.2 
NBU.8 Using the methods described,8 with 4 negative specimens prepared from equal parts 
NPP and FVIIIDP and 4 positive specimens prepared by diluting a known inhibitor in 
FVIIIDP to 1.0 NBU tested over 3 days, the LOD with BSA was calculated to be 0.30 NBU. 
For 30 specimens from healthy paid donors with no history of a bleeding disorder, mean ± 
SD was 0.060 ± 0.069, and LOD calculated as mean ± 3 SD was 0.267. The LOD of the 
CDC-NBA with BSA thus estimated to be 0.3 NBU is consistent with other findings 
presented here indicating that the CDC-NBA with BSA gives slightly higher values than the 
CDC-NBA with FVIIIDP at low levels.
This study demonstrates that substitution of BSA for FVIIIDP in the CDC-NBA is 
satisfactory, as reported for the original NBA.5–7 As previously noted,6,7 von Willebrand 
factor is not required in the diluent if present in the assay substrate. Among the nonplasma 
diluents tested, differences were small; however, diluents containing BSA may be preferable 
for specimens requiring extensive predilution to maintain protein concentration. Use of 
nonplasma diluents actually improved stability and could reduce both cost and the variability 
introduced by adding different FVIIIDP reagents. IB-NPP, as recommended in the original 
NBA,3 showed greater stability than unbuffered or HEPES- buffered NPP. The consistent 
use of imidazole buffer throughout the assay may be advantageous.
The threshold for positivity of ≥0.5 NBU for the CDC- NBA with FVIIIDP previously 
established7 has been validated by measurement of IgG4 anti-FVIII antibodies,8 which have 
been shown to correlate with the presence of a functional inhibitor.9 BSA substitution 
required adjustment of the threshold to achieve the same results, a finding not previously 
reported. The observed drop in VIII:C during incubation accounted for the difference and 
was not an aberration in a single experiment, as it was seen in paired specimens throughout 
the study. Postincubation, the control mixture with FVIIIDP was consistently lower than 
with BSA. Because some types of immunodepleted FVIIIDP produce aberrant results,10 
only FVIIIDP from congenitally deficient patients, confirmed to be inhibitor-negative, was 
used. Additional buffering of FVIIIDP might resolve the difference; however, it seems 
unnecessary to add that cost if nonplasma diluents can be used.
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In practice, few laboratories have enough specimens to set reference ranges for FVIII 
inhibitors. The ISTH has defined a positive inhibitor based on clinical practice1; however, 
our findings show that method modifications can change the results. Multilaboratory studies 
using standardized test protocols and recommended reagents are needed to validate this 
important parameter and to produce guidelines to reduce interlaboratory variability.
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FIGURE 1. 
Stability over 2-h incubation at 37°C of a 1:1 mixture of normal pool plasma (NPP) and 
diluent. (A). Change in factor VIII (FVIII) activity and pH of NPP unbuffered or buffered 
with imidazole or HEPES with factor VIII-deficient plasma (FVIIIDP), 4% bovine serum 
albumin (BSA) or an inhibitor-negative patient plasma. (B). Imidazole-buffered NPP with 
FVIIIDP, BSA, imidazole-buffered BSA (IB-BSA) and imidazole buffer (IB). Mean of 
duplicate determinations on triplicate specimens
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TABLE 1
(A) Comparison of results with different diluents in the control mixture: factor VIII-deficient plasma 
(FVIIIDP), 4% bovine serum albumin (BSA), imidazole- buffered BSA (IB-BSA) or imidazole buffer (IB). 
(B) Summary of performance characteristics of the CDC-modified Nijmegen-Bethesda assay (CDC-NBA) 
using FVIIIDP or BSA in the control mixture and for predilution
A. FVIIIDP BSA IB-BSA IB
All Data (n = 326)
 Range 0–1.6 0–1.7 0–1.9 0–1.8
 Median (IQR) 0 (0–0.2) 0.2 (0–0.3)* 0.2 (0.1–0.3)* 0.2 (0.1–0.3)*
Positives (n = 15)a
 Range 0.5–1.6 0.3–1.7 0.4–1.9 0.4–1.8
 Median (IQR) 0.6 (0.5–1.0) 0.6 (0.6–1.0) 0.7 (0.5–0.9) 0.8 (0.6–1.1)
Negatives (n = 311)a
 Range 0–0.4 0–0.6 0–0.6 0–0.7
 Median (IQR) 0 (0–0.2) 0.2 (0–0.3)* 0.2 (0.1–0.3)* 0.2 (0.1–0.3)*
B. FVIIIDP BSA
n % n %
Between runs
 Positive Control 114 CV: 10.3 76 CV: 12.8
 Negative Control 117 CV: 9.8 72 CV: 9.7
Within runs
 Positive Control 10 CV: 4.8 10 CV: 6.6
 Negative Control 10 CV: 5.3 10 CV: 6.7
Sensitivity
 Positive patients 51b 100 33a 97
 Negative patients 581b 98.8 1206a 98.8
Specificity
 Healthy subjects 30 100 30 100
*Significantly different from FVIIIDP results by Kruskal-Wallis test at P < .05.
a
Defined as positive if ≥0.5 NBU and negative if <0.5 NBU using FVIIIDP.
bSpecimens from patients with or without clinical history of inhibitor.
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